Sarepta Therapeutics Inc. (SRPT:NASDAQ) is drawing sharply contrasting analyst opinions as it works to rebuild its Duchenne muscular dystrophy (DMD) franchise and advance its RNA-based therapeutic pipeline. Recently, H.C. Wainwright reiterated a "Sell" rating with a US$5 price target, while Wedbush maintained a "Buy" rating and US$35 target following new preclinical data for Sarepta's myotonic dystrophy type 1 (DM1) candidate.
The differing assessments reflect uncertainty surrounding the company's commercial outlook, the clinical prospects of its investigational therapies, and the potential for its expanding pipeline to offset pressure on its existing business.
Key Investor Takeaways
-
Wedbush maintained a "Buy" rating and US$35 price target, citing the potential of Sarepta's expanding RNA pipeline, including SRP-1003 and SRP-1005.
-
H.C. Wainwright reiterated a "Sell" rating and US$5 target, questioning whether preclinical DM1 results meaningfully improve SRP-1003's clinical prospects following Novartis' Phase 3 setback.
-
Q2 2026 revenue declined 34% year-over-year to US$401.3 million, primarily reflecting lower ELEVIDYS sales and the absence of a prior-year Roche milestone payment.
-
Sarepta reported US$945 million in cash, cash equivalents, restricted cash and investments on June 30, 2026.
-
The company’s next catalyst is its Q3 results on November 5, followed by a conference call at 4:30 p.m. ET.
-
Institutional investors, led by BlackRock, State Street, and Vanguard, held substantial reported positions as of June 30, 2026.
Recent Updates from Sarepta
Sarepta reported Q2 2026 revenue of US$401.3 million, down from US$611.1 million in the same period of 2025. The company recorded a GAAP net loss of US$4.9 million, compared with net income of US$196.9 million a year earlier. On a non-GAAP basis, however, Sarepta reported net income of US$78.6 million, or US$0.64 per diluted share, compared with US$215.2 million, or US$2.02 per diluted share, in the prior-year quarter. That revenue decline primarily reflected lower ELEVIDYS sales following the product's revised label, which limits its indicated use to ambulatory patients, as well as the absence of a prior-year milestone payment from Roche related to Japanese regulatory approval. Sarepta reported US$945 million in cash, cash equivalents, restricted cash, and investments on June 30, 2026.
On October 14, 2026, Sarepta presented new preclinical findings for SRP-1003, its investigational small interfering RNA (siRNA) treatment for DM1, at the 2026 Oligonucleotide Therapeutics Society Annual Meeting. In patient-derived muscle cells, the candidate achieved up to approximately 80% knockdown of disease-causing DMPK messenger RNA in both the nuclear and cytoplasmic compartments. The company also reported reductions in toxic RNA foci. In mouse models, the treatment reduced nuclear RNA foci across skeletal muscle, the diaphragm and the heart, and a surrogate siRNA corrected MBNL-dependent RNA splicing. Sarepta said the findings support the candidate's ability to reach and reduce disease-causing RNA within the nucleus, where key mechanisms underlying DM1 originate.
The company also underwent a leadership transition in July. Michael Severino, M.D., became CEO on July 28, succeeding Doug Ingram, who retired from the position and agreed to serve as a consultant through December 31, 2026, according to the company's SEC leadership transition filing. Sarepta is scheduled to report Q3 2026 financial results after market close on November 5, followed by a conference call at 4:30 p.m. ET, according to its October 22 announcement.
Analysts and Research Reports Offer Mixed Ratings
Analyst opinions on Sarepta remain divided, with the most pronounced disagreement coming from Wedbush and H.C. Wainwright.
Wedbush analyst Yun Zhong maintained a "Buy" rating and US$35 price target on October 16, 2026, according to TipRanks' coverage of the analyst note. Zhong's assessment focused on Sarepta's expanding RNA-based therapeutic pipeline, particularly the recent SRP-1003 findings in DM1. The analyst viewed the reduction of toxic DMPK transcripts within the nucleus, alongside improvements in RNA splicing, as encouraging evidence of the candidate's potential disease-modifying activity.
Zhong also highlighted SRP-1005, Sarepta's investigational Huntington's disease candidate developed in partnership with Arrowhead Pharmaceuticals. Initial partner data indicating target knockdown in key deep brain regions following subcutaneous administration added another potential development opportunity to the company's pipeline. Wedbush's position suggests that progress in RNA-targeted treatments could provide additional opportunities alongside Sarepta's established DMD franchise.
H.C. Wainwright analyst Mitchell Kapoor took a substantially more cautious position, reiterating a "Sell" rating and US$5 target on October 19, 2026. According to Investing.com's coverage of the analyst report, the firm maintained its assessment despite Sarepta's October 14 preclinical announcement. Kapoor questioned whether the stronger knockdown results observed in laboratory models provided sufficient evidence to increase the likelihood of SRP-1003 ultimately gaining regulatory approval.
A central concern was the clinical setback involving del-desiran, an investigational DM1 treatment developed by Novartis. The treatment's Phase 3 HARBOR study failed to meet its primary endpoint, although Novartis reported evidence of activity in secondary endpoints and exploratory analyses. H.C. Wainwright did not view Sarepta's preclinical findings as sufficient to overcome the uncertainty created by that result.
Other recent analyst assessments reflect the uncertainty surrounding the company. TD Cowen analyst Ritu Baral maintained a "Hold" rating and US$17 target on October 21, while Piper Sandler analyst Biren Amin maintained a "Hold" rating and US$20 target on October 19. Leerink Partners reiterated a Hold rating with a US$20 target on October 15. RBC Capital maintained its "Sector Perform" rating and lowerered its price target from US$19 to US$17.
The analyst ratings and price-target history for Sarepta provide a broader comparison of these assessments. Additional recent ratings include:
-
On October 9, 2026, Tazeen Ahmad of Bank of America reiterated a "Sell" rating with a price target of US$18.
-
On October 2, 2026, Yanan Zhu of Wells Fargo reiterated a "Buy" rating with a price target of US$38.
-
On September 30, 2026, Anupam Rama of J.P. Morgan reiterated a "Hold" rating but lowered the price target from US$23 to US$20.
-
On September 28, 2026, Gil Blum of Needham reiterated a "Sell" rating.
-
On September 28, 2026, Lachlan Hanbury-Brown of William Blair reiterated a "Hold" rating.
-
On September 28, 2026, Yigal Nochomovitz of Citi reiterated a "Sell" rating with a price target of US$13.
-
On August 10, 2026, Gavin Clark-Gartner of Evercore ISI reiterated a "Hold" rating with a price target of US$19.
-
On August 7, 2026, Eliana Merle of Barclays reiterated a "Hold" rating with a price target of US$20.
-
On August 6, 2026, Michael Ulz of Morgan Stanley reiterated a "Hold" rating with a price target of US$25.
Taken together, these ratings illustrate a market weighing the potential of Sarepta's research programs against declining product revenue, regulatory uncertainty and the difficulty of translating promising preclinical findings into successful clinical outcomes.
The DMD Market Shows Need
Sarepta operates in the rare disease therapeutics sector, with a focus on genetic medicines and RNA-targeted treatments for neuromuscular disorders. Its portfolio includes gene therapy and RNA-based approaches targeting conditions such as DMD, DM1, and Huntington's disease.
The Duchenne Muscular Dystrophy market was worth US$16.38 billion in 2025 and is expected to grow to US$62.13 billion by 2030, with a massive expected CAGR of 30.5%. North America is currently the largest market in need of muscular dystrophy treatments.
In February 2026, IQVIA discussed the global pharma market projection for 2026, noting that total drug usage is expected to approach four trillion doses daily by 2030. It wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."
Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He wrote that pharma funding had fallen from 2024 but noted that "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."
BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."
Ownership and Share Structure1
Institutions hold about 95.50% of Sarepta, while management and insiders own approximately 4.50%.
The largest disclosed holders are BlackRock Inc. (17.98%) and State Street Corp. (8.44%).
The company has roughly 105.63 million shares outstanding, a market capitalization of about US$2.03 billion, and a 52-week trading range of approximately US$14.68 to US$24.68.
No verified insider open-market buys or sells were found for the last six months.
No current warrants were found. Public records show one historical share restructure.
Common Questions from Investors
What did H.C. Wainwright and Wedbush say about Sarepta?
H.C. Wainwright reiterated "Sell" with US$5 target in October 2026 due to core franchise weakness and clinical risks; Wedbush kept "Buy" at US$35, citing RNA pipeline expansion and DM1 preclinical progress.
What were Sarepta's latest financial results?
Q2 2026 revenue was US$401.25 million with a net loss of US$4.89 million, down from prior-year profit.
What is the current analyst consensus on SRPT?
Consensus is Hold with average targets around US$21-22 from multiple firms.
How does ownership look for Sarepta?
Institutions dominate with top holders BlackRock (~18%) and State Street (~8.4%) as of June 30, 2026 filings; shares outstanding approximate 106 million.
| Want to be the first to know about interesting Biotechnology / Pharmaceuticals investment ideas? Sign up to receive the FREE Streetwise Reports' newsletter. | Subscribe |
Important Disclosures:
- Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee.
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
- This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.
For additional disclosures, please click here.
1. Ownership and Share Structure Information
Ownership percentages, named holders, share count, market capitalization, and the 52-week range for Sarepta were compiled from the company's public filings and investor materials, exchange notices, insider-trade reports (SEDI / equivalent), and third-party data providers. Figures are as of 2026-10-30 unless a source was dated earlier. Pie slices are normalized to 100% of basic shares outstanding; retail is the residual after disclosed institutions, management, insiders, and strategic holders. Warrant terms are current outstanding series only. Restructures are historical consolidations, splits, and symbol or name changes. Insider buying and selling covers open-market trades from 2026-04-30 through 2026-10-30 and excludes option exercises. These are public-source estimates and can differ from a later official register.
